Dupont Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Dupont Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-38,855	Closed	-$194K	–	1932
2021 Q1	$194K	Buy	38,855 +14,602	+60%	+$118K	﹤0.01%	1280
2020 Q4	$307K	Buy	24,253 +10,487	+76%	+$120K	0.01%	1027
2020 Q3	$135K	Sell	13,766 -16,759	-55%	-$165K	﹤0.01%	1172
2020 Q2	$304K	Buy	+30,525	New	+$293K	0.01%	967
2018 Q2	–	Sell	-37,494	Closed	-$859K	–	1055
2018 Q1	$859K	Hold	37,494	–	–	0.02%	554
2017 Q4	$970K	Buy	+37,494	New	+$755K	0.02%	520

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dupont Capital Management's CNCE Position: Q2 2021 in Review

Dupont Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2021, closing a stake of 38,855 shares — an estimated $194K sold.

Dupont Capital Management first reported a position in CNCE in Q4 2017 and held it in 6 quarters. The position peaked at $970K in Q4 2017. 79 funds tracked by Wall St. Rank hold CNCE as of Q2 2021.

Dupont Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Dupont Capital Management sold 38,855 Concert Pharmaceuticals, Inc. shares in Q2 2021, an estimated $194K.
Dupont Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 6 quarters.
Dupont Capital Management's Concert Pharmaceuticals, Inc. position peaked at $970K in Q4 2017.
79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2021.

Based on Dupont Capital Management's 13F filing for Q2 2021, filed 30 Jul 2021.